Diagnostic biomarkers differentiating metastatic melanoma patients from healthy controls identified by an integrated MALDI-TOF mass spectrometry/bioinformatic approach-Reference-Cited by-同舟云学术

Diagnostic biomarkers differentiating metastatic melanoma patients from healthy controls identified by an integrated MALDI-TOF mass spectrometry/bioinformatic approach

Published:2007-06 Issue:6 Volume:1 Page:605-620
ISSN:1862-8346
Container-title:PROTEOMICS – Clinical Applications
language:en
Short-container-title:Prot. Clin. Appl.

Author:

Matharoo-Ball Balwir,Ratcliffe Lucy,Lancashire Lee,Ugurel Selma,Miles Amanda K.,Weston Daniel J.,Rees Robert,Schadendorf Dirk,Ball Graham,Creaser Colin S.

Publisher

Wiley

Subject

Clinical Biochemistry

Reference56 articles.

1. Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma

2. Estimates of stage-specific survival are altered by changes in the 2002 American Joint Committee on Cancer staging system for melanoma

3. Evaluation of new putative tumor markers for melanoma

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proteomics as a tool to improve novel insights into skin diseases: what we know and where we should be going;Frontiers in Surgery;2022-10-21

2. Imaging Mass Spectrometry-Based Proteomic Analysis to Differentiate Melanocytic Nevi and Malignant Melanoma;Cancers;2021-06-26

3. Development of a Bioinformatics Framework for Identification and Validation of Genomic Biomarkers and Key Immunopathology Processes and Controllers in Infectious and Non-infectious Severe Inflammatory Response Syndrome;Frontiers in Immunology;2020-03-31

4. Liquid biomarkers in melanoma: detection and discovery;Molecular Cancer;2018-01-17

5. Melanoma Biomarkers in Circulation;Cancer Biomarkers in Body Fluids;2016-11-26